January 14, 2026CureusOpen Access

Cardiac Valvular Incompetence Associated With Selective Serotonin Reuptake Inhibitors (SSRIs): A Disproportionality and Risk Factor Analysis From Global Safety Reports

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Cardiac valvular incompetence (n=1462). Intervention: Selective serotonin reuptake inhibitors (SSRIs) vs. SSRI reports without valvular incompetence (non-cases). Primary outcome: Cardiac valvular incompetence (OR 2.011, 95% CI 1.055-3.833, p=0.0337).

View Full Paper

Ask AI

Bookmark

Key result

Among SSRI users, concomitant use of medications associated with serotonin dysregulation and valvopathy independently increased the odds of cardiac valvular incompetence (OR 2.011).

Why the study?

Does the use of SSRIs increase the risk of cardiac valvular incompetence?

Population

Users of six SSRIs reported in VigiBase

Comparison

Six SSRIs (sertraline, paroxetine, fluoxetine, fluvoxamine, citalopram, and escitalopram)

Design

Pharmacovigilance database disproportionality and risk factor analysis

Authors

ACAdrian Chin Yan ChanBayer (United States)YHYue Han

Discussion

Member takes

Implication

Cardiac comorbidities warrant valvopathy vigilance with serotonergic agents; observational data leave independent SSRI causality unresolved.

Study Design

Type

Observational (n=1,462)

Structured PICO

Does the use of SSRIs increase the risk of cardiac valvular incompetence?

Population

1,462 global pharmacovigilance reports of patients exposed to SSRIs who developed cardiac valvular incompetence, analyzed to identify disproportionality signals and risk factors.

Exposure

Use of SSRIs (sertraline, paroxetine, fluoxetine, fluvoxamine, citalopram, and escitalopram).

Comparator

Other reports in the VigiBase pharmacovigilance database (disproportionality analysis).

Outcome

Cardiac valvular incompetence (particularly pulmonary and tricuspid valve incompetence).safety

Main Result

Odds Ratio: 2.011 (95% CI 1.055–3.833)

p-value: p=0.0337

Global pharmacovigilance data suggest a potential association between certain SSRIs (paroxetine, sertraline, fluoxetine) and cardiac valvular incompetence, with risk amplified by pre-existing cardiac comorbidities and concomitant serotonergic medications.

Limitations

Spontaneous reporting can bias reporting, including underreporting and stimulated reporting.
High number of cases lacked age data, limiting demographic comparisons.
Lack of clinical validation such as echocardiographic confirmation.
No indication of a temporal relationship between starting SSRI antidepressants and valvopathy, limiting causal inference.
Potential confounding by indication, as depression may increase cardiovascular risk.

Cite This Study

Chan et al. (2026) conducted an observational in Cardiac valvular incompetence (n=1,462). Selective serotonin reuptake inhibitors (SSRIs) vs. SSRI reports without valvular incompetence (non-cases) was evaluated on Cardiac valvular incompetence (OR 2.011, 95% CI 1.055-3.833, p=0.0337). Among SSRI users, concomitant use of medications associated with serotonin dysregulation and valvopathy independently increased the odds of cardiac valvular incompetence (OR 2.011).

synapsesocial.com/papers/6a967d6e33d7b00ae7bb81aa https://doi.org/10.7759/cureus.101519

View Full Paper

Ask AI

Bookmark

January 14, 2026CureusOpen Access

Cardiac Valvular Incompetence Associated With Selective Serotonin Reuptake Inhibitors (SSRIs): A Disproportionality and Risk Factor Analysis From Global Safety Reports

View Full Paper

Ask AI

Bookmark

Key result

Among SSRI users, concomitant use of medications associated with serotonin dysregulation and valvopathy independently increased the odds of cardiac valvular incompetence (OR 2.011).

Why the study?

Does the use of SSRIs increase the risk of cardiac valvular incompetence?

Population

Users of six SSRIs reported in VigiBase

Comparison

Six SSRIs (sertraline, paroxetine, fluoxetine, fluvoxamine, citalopram, and escitalopram)

Design

Pharmacovigilance database disproportionality and risk factor analysis

Authors

ACAdrian Chin Yan ChanBayer (United States)YHYue Han

Discussion

Member takes

Implication

Cardiac comorbidities warrant valvopathy vigilance with serotonergic agents; observational data leave independent SSRI causality unresolved.

Study Design

Type

Observational (n=1,462)

Structured PICO

Does the use of SSRIs increase the risk of cardiac valvular incompetence?

Population

1,462 global pharmacovigilance reports of patients exposed to SSRIs who developed cardiac valvular incompetence, analyzed to identify disproportionality signals and risk factors.

Exposure

Use of SSRIs (sertraline, paroxetine, fluoxetine, fluvoxamine, citalopram, and escitalopram).

Comparator

Other reports in the VigiBase pharmacovigilance database (disproportionality analysis).

Outcome

Cardiac valvular incompetence (particularly pulmonary and tricuspid valve incompetence).safety

Main Result

Odds Ratio: 2.011 (95% CI 1.055–3.833)

p-value: p=0.0337

Limitations

Spontaneous reporting can bias reporting, including underreporting and stimulated reporting.
High number of cases lacked age data, limiting demographic comparisons.
Lack of clinical validation such as echocardiographic confirmation.
No indication of a temporal relationship between starting SSRI antidepressants and valvopathy, limiting causal inference.
Potential confounding by indication, as depression may increase cardiovascular risk.

Cite This Study

synapsesocial.com/papers/6a967d6e33d7b00ae7bb81aa https://doi.org/10.7759/cureus.101519

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark